JWM
BMRN icon

JPL Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

JPL Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.72K Sell
100
-70
-41% -$3.83K ﹤0.01% 730
2026
Q1 		$9.6K Buy
+170
New +$9.91K ﹤0.01% 539
2025
Q4 		– Sell
-100
Closed -$5.42K – 246
2025
Q3 		$5.42K Buy
+100
New +$5.72K ﹤0.01% 651

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

JPL Wealth Management's BMRN Position: Q2 2026 in Review

JPL Wealth Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 41% in Q2 2026, selling an estimated $3.83K and leaving 100 shares worth $5.72K. The position accounts for ﹤0.01% of the portfolio, ranked #730.

JPL Wealth Management first reported a position in BMRN in Q3 2025 and has held it in 3 quarters since. The position peaked at $9.6K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • JPL Wealth Management held 100 shares of BioMarin Pharmaceuticals worth $5.72K as of Q2 2026.
  • JPL Wealth Management sold 70 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.83K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of JPL Wealth Management's portfolio in Q2 2026, its #730 holding.
  • JPL Wealth Management first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • JPL Wealth Management's BioMarin Pharmaceuticals position peaked at $9.6K in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on JPL Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.